Insider buying
~$5.2K35K sh @ $0.149
Traded Nov 11 · filed 2 days later
The CEO of Aim Immunotech paid $5.2K out of pocket for Aim Immunotech shares. Shares held went up 12% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 6, 2026 · Filed Nov 6, 2026
The CEO of Aim Immunotech paid $3.2K out of pocket for Aim Immunotech shares. Shares held went up 11% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$3,167
Shares × reported transaction price
<$25K
+10.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 17 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2025 ($640K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-09-30. The proxy names Thomas K. Equels as CEO for that year. A size comparison, not a judgement
88 days after results of Aug 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.155 on Nov 6, 2026, within 2% of its 52-week low, after an 18% drop over the previous 30 trading days
52-week range $0.1521 (Nov 5, 2026) to $1.68 (Nov 7, 2025), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.1901 on Sep 25, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider buying
Traded Nov 11 · filed 2 days later
The CEO of Aim Immunotech paid $5.2K out of pocket for Aim Immunotech shares. Shares held went up 12% with this purchase.
Insider buying
Traded Nov 10 · filed 2 days later
The CEO of Aim Immunotech paid $5.4K out of pocket for Aim Immunotech shares. Shares held went up 15% with this purchase.
Insider buying
Traded Nov 9 · filed 1 day later
The CEO of Aim Immunotech paid $5.1K out of pocket for Aim Immunotech shares. Shares held went up 14% with this purchase.
Thomas K Equels, CEO & President's past purchases, 90 days after disclosure: 5 buys, median −40.0 pts vs S&P 500, beat it 0 of 5 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.